#United States #Boston #CereVasc #NPH #eShunt System

CereVasc, Inc. Successfully Completes Enrollment in STRIDE Trial

CereVasc, Inc., a Boston-based medical device innovator, has recently announced a pivotal advancement in their efforts to improve treatments for normal pressure hydrocephalus (NPH). The completion of patient enrollment in their STRIDE pivotal trial represents a significant milestone for the company's investigational eShunt System.

NPH is a serious medical condition affecting roughly 800,000 people in the U.S. and often goes unrecognized. Patients suffering from NPH experience symptoms like cognitive decline, gait disturbances, and urinary incontinence. The prevailing treatment has been the ventriculo-peritoneal (VP) shunt, which has seen little innovation for over six decades. CereVasc aims to change this by introducing the eShunt System, a minimally invasive alternative designed to offer hope to many patients who are not suited for traditional surgical interventions.

The STRIDE trial stands as the largest and first randomized controlled trial focusing on the eShunt System, conducted across 32 clinical sites. By directly comparing this novel system to the established VP shunt among elderly patients with NPH, CereVasc seeks to gather data crucial for securing FDA Premarket Approval (PMA). The trial is pivotal not just for its size, but because it addresses a critical need for new treatment modalities in the face of aging populations and increasing NPH diagnoses.

According to Dan Levangie, Chairman and CEO of CereVasc, completing this enrollment phase brings the company closer to generating essential data for their PMA submission. He emphasized the cooperation of clinical investigators, site teams, patients, and employees in achieving this important milestone.

The focus now shifts to completing the remaining treatment and follow-up procedures for enrolled patients, maintaining a commitment to delivering an effective treatment option for the many individuals grappling with the challenges posed by NPH.

Dr. Charles Matouk from Yale Neurosurgery, echoing Levangie's sentiments, noted that the successful enrollment reflects a strong commitment within the clinical community to explore less invasive treatment options and potentially enhance the quality of life for those affected by NPH. As the study progresses according to its protocol, the anticipation for topline data builds, with results expected to illuminate the efficacy and safety of the eShunt System as compared to conventional methods.

At its core, the eShunt System utilizes a novel, minimally invasive technique that involves an endovascular approach—aiming to reposition how hydrocephalus is treated. For patients who may be unfit for conventional shunt surgery, this could signify a transformative change in their treatment journey. The implications extend beyond just NPH, as CereVasc continues to pave the way in developing innovative solutions aimed at addressing various neurological conditions.

The trial’s completion further establishes CereVasc's role at the forefront of medical innovation within this sphere, demonstrating a persistent effort to not only enhance existing treatments but also substantially alter the treatment landscape for neurodegenerative issues.

For the latest updates on the STRIDE trial and the eShunt System, interested parties can refer to www.nphstridestudy.com. As the trial embarks on its next phases, stakeholders and the general public will await the outcomes, providing a glimpse into the future of NPH management and beyond.

About CereVasc, Inc.

CereVasc, Inc., situated in Massachusetts, specializes in developing groundbreaking, minimally invasive treatments for neurological diseases. The eShunt System is just the beginning of their innovations aimed at improving patient care and outcomes in the field of neurology. Explore more about their commitments and technologies at www.cerevasc.com.

Note: The eShunt System remains investigational and has yet to secure FDA approval for commercial use.